Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2018-01-02
|
tabelecleucel (formerly known as ATA129) |
rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD) |
3 |
Atara Biotherapeutics (USA - CA) |
Cancer - Oncology |
2018-01-02
|
tislelizumab (BGB-A317) |
hepatocellular carcinoma |
3 |
BeiGene (China) |
Cancer - Oncology |
2017-12-29
|
HyLeukin® |
advanced solid tumors |
1b |
Genexine (Republic of Korea) |
Cancer - Oncology |
2017-12-27
|
Iomab-B (131I apamistamab) |
acute myeloid leukemia (AML) |
3 |
Actinium Pharmaceuticals (USA - NJ) |
Cancer - Oncology |
2017-12-27
|
imeglimin |
type 2 diabetes |
3 |
Poxel (France) Sumitomo Dainippon Pharma (Japan) |
Metabolic diseases |
2017-12-27
|
|
locally advanced cutaneous melanoma |
|
Provectus Pharmaceuticals (USA - TN) |
Cancer - Oncology |
2017-12-27
|
VB-111 (ofranergene obadenovec) |
platinum-resistant ovarian cancer |
3 |
VBL Therapeutics (Israel) |
Cancer - Oncology |
2017-12-27
|
eteplirsen |
Duchenne Muscular Dystrophy |
2b |
Sarepta Therapeutics (USA - MA) |
Genetic diseases - Neuromuscular diseases - Rare diseases |
2017-12-26
|
AG-270 |
tumor types carrying an MTAP deletion |
1 |
Peregrine Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2017-12-22
|
Yeliva™ (ABC294640) |
cholangiocarcinoma |
2a |
Redhill Biopharma (Israel) |
Cancer - Oncology |
2017-12-22
|
anabasum (JBT-101 ) |
systemic lupus erythematosus (SLE) |
2 |
Corbus Pharmaceuticals (USA - MA) |
Autoimmune diseases |
2017-12-22
|
SCB-808 (biosimilar etanercept) |
rheumatoid arthritis and other autoimmune diseases |
1 |
Clover Biopharmaceuticals (China) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2017-12-21
|
caplacizumab |
acquired thrombotic thrombocytopenic purpura (TTP) |
1 |
Ablynx (Belgium) |
Autoimmune diseases - Rare diseases |
2017-12-21
|
SNF472 - hexasodium phytate |
calciphylaxis |
|
Sanifit (Spain - Switzerland) |
Rare diseases - Cardiovascular diseases |
2017-12-21
|
gemcabene |
NASH (non-alcoholic steatohepatitis)/nonalcoholic fatty liver disease (NAFLD) - Familial Partial Lipodystrophy (FPL) |
2a |
Gemphire Therapeutics (USA - Mich) |
Liver diseases - Hepatic diseases |
2017-12-21
|
Revlimid® (lenalidomide) and rituximab |
previously untreated follicular lymphoma |
3 |
Celgene (USA - NJ) Lysarc (France) |
Cancer - Oncology |
2017-12-21
|
PCM-075 (1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt) |
acute myeloid leukemia (AML) |
1b-2 |
Trovagene (USA - CA) |
Cancer - Oncology |
2017-12-21
|
SAB-136 |
antibiotic-resistant bacteria. Mycoplasma hominis |
1 |
SAB Biotherapeutics (USA - SD) |
Infectious diseases |
2017-12-21
|
BAN2401 |
Alzheimer's disease |
2 |
Eisai (Japan) Biogen (USA - MA) |
Neurodegenerative diseases |
2017-12-20
|
JHL1149 (biosimilar version of bevacizumab - Avastin®) |
|
1 |
JHL Biotech (Taiwan) |
Cancer - Oncology |